DK1551868T3 - Faktor involveret i metastase og anvendelser deraf - Google Patents

Faktor involveret i metastase og anvendelser deraf

Info

Publication number
DK1551868T3
DK1551868T3 DK03769423T DK03769423T DK1551868T3 DK 1551868 T3 DK1551868 T3 DK 1551868T3 DK 03769423 T DK03769423 T DK 03769423T DK 03769423 T DK03769423 T DK 03769423T DK 1551868 T3 DK1551868 T3 DK 1551868T3
Authority
DK
Denmark
Prior art keywords
metastasis
polypeptide
amino acid
extracellular matrix
sequence according
Prior art date
Application number
DK03769423T
Other languages
Danish (da)
English (en)
Inventor
Anke Klippel-Giese
Joerg Kaufmann
Rolf Schwarzer
Original Assignee
Silence Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silence Therapeutics Ag filed Critical Silence Therapeutics Ag
Application granted granted Critical
Publication of DK1551868T3 publication Critical patent/DK1551868T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03769423T 2002-10-18 2003-10-20 Faktor involveret i metastase og anvendelser deraf DK1551868T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02023384 2002-10-18
PCT/EP2003/011604 WO2004035615A2 (en) 2002-10-18 2003-10-20 Factor involved in metastasis and uses thereof

Publications (1)

Publication Number Publication Date
DK1551868T3 true DK1551868T3 (da) 2009-04-20

Family

ID=32103889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03769423T DK1551868T3 (da) 2002-10-18 2003-10-20 Faktor involveret i metastase og anvendelser deraf

Country Status (19)

Country Link
US (2) US20060240022A1 (ja)
EP (2) EP1551868B1 (ja)
JP (2) JP4820092B2 (ja)
KR (1) KR101154130B1 (ja)
CN (1) CN100564524C (ja)
AT (1) ATE420102T1 (ja)
AU (2) AU2003278112A1 (ja)
BR (1) BR0315411A (ja)
CA (1) CA2501333A1 (ja)
CY (1) CY1110313T1 (ja)
DE (1) DE60325754D1 (ja)
DK (1) DK1551868T3 (ja)
ES (1) ES2319891T3 (ja)
IL (1) IL167801A (ja)
MX (1) MXPA05004134A (ja)
PT (1) PT1551868E (ja)
SI (1) SI1551868T1 (ja)
WO (1) WO2004035615A2 (ja)
ZA (1) ZA200502483B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405292B2 (en) 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
MXPA05001355A (es) 2002-08-05 2005-09-30 Atugen Ag Formas nuevas adicionales de moleculas de arn de interferencia.
EP1551868B1 (en) * 2002-10-18 2009-01-07 Silence Therapeutics AG Factor involved in metastasis and uses thereof
MX2007002043A (es) 2004-08-16 2007-10-11 Quark Biotech Inc Usos terapeuticos de los inhibidores del rtp801.
CN100357323C (zh) * 2006-01-05 2007-12-26 清华大学 一种细胞迁移相关蛋白及其编码基因与应用
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
GB2450840B (en) 2006-05-11 2010-12-29 Quark Pharmaceuticals Inc Screening Systems Utilizing RTP801
JP2010518880A (ja) 2007-02-26 2010-06-03 クアーク・ファーマスーティカルス、インコーポレイテッド Rtp801のインヒビター及びその疾患の治療における使用
WO2010021718A1 (en) 2008-08-19 2010-02-25 Nektar Therapeutics Complexes of small-interfering nucleic acids
WO2011035065A1 (en) 2009-09-17 2011-03-24 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
ES2872349T3 (es) 2012-09-12 2021-11-02 Quark Pharmaceuticals Inc Moléculas de oligonucleótidos bicatenarios para DDIT4 y métodos de uso de las mismas

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1695978A1 (en) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
EP0934331B1 (de) 1996-08-30 2002-11-27 Jens Peter Fürste Spiegelselektion und spiegelevolution von nucleinsäuren
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2326823A1 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2003516114A (ja) * 1999-06-11 2003-05-13 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 50個のヒト分泌タンパク質
US6133032A (en) * 1999-09-09 2000-10-17 Isis Pharmaceutical Inc. Antisense modulation of PI3 kinase p110 beta expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
US6673545B2 (en) * 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
AU2002220920A1 (en) * 2000-12-08 2002-06-18 Oxford Biomedica (Uk) Limited Method for identification of genes involved in specific diseases
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
EP2314716A1 (en) * 2002-08-20 2011-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
EP1551868B1 (en) * 2002-10-18 2009-01-07 Silence Therapeutics AG Factor involved in metastasis and uses thereof
MX2007002043A (es) * 2004-08-16 2007-10-11 Quark Biotech Inc Usos terapeuticos de los inhibidores del rtp801.

Also Published As

Publication number Publication date
PT1551868E (pt) 2009-04-06
EP1551868A2 (en) 2005-07-13
CN100564524C (zh) 2009-12-02
JP2006520183A (ja) 2006-09-07
SI1551868T1 (sl) 2009-06-30
CY1110313T1 (el) 2015-01-14
US20100285038A1 (en) 2010-11-11
MXPA05004134A (es) 2005-10-05
KR101154130B1 (ko) 2012-06-12
BR0315411A (pt) 2005-08-16
WO2004035615A3 (en) 2004-06-03
EP1551868B1 (en) 2009-01-07
KR20050056244A (ko) 2005-06-14
CN1705746A (zh) 2005-12-07
JP2011125339A (ja) 2011-06-30
DE60325754D1 (de) 2009-02-26
IL167801A (en) 2012-10-31
AU2003278112A1 (en) 2004-05-04
ES2319891T3 (es) 2009-05-14
JP4820092B2 (ja) 2011-11-24
ATE420102T1 (de) 2009-01-15
ZA200502483B (en) 2005-11-30
US20060240022A1 (en) 2006-10-26
EP2072619A1 (en) 2009-06-24
WO2004035615A2 (en) 2004-04-29
CA2501333A1 (en) 2004-04-29
AU2010246370A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
CY1110313T1 (el) Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του
Joester et al. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system
Zhou et al. Evidence that HetR protein is an unusual serine-type protease
Doliana et al. EMILIN, a component of the elastic fiber and a new member of the C1q/tumor necrosis factor superfamily of proteins
Leyh et al. The DNA sequence of the sulfate activation locus from Escherichia coli K-12.
Yonemura et al. Protein composition of silk filaments spun under water by caddisfly larvae
FI882456A0 (fi) Human proapolipoprotein a-i expression.
AR039003A1 (es) Composiciones y metodos para alterar el contenido de tocotrienoles
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69926729D1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
ATE528398T1 (de) Transkriptionsfaktor-gen osnacx aus reis und verwendung davon zur verbesserung der toleranz von pflanzen gegenüber trockenheit und salz
ATE317897T1 (de) System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
ATE198083T1 (de) Thermostable nukleinsäure polymerase
IS4884A (is) Ret bindill til örvunar vaxtar tauga og thvagfæra
NO20024240L (no) Nye arylfruktose-1,6-bisfosfataseinhibitorer
DK1472344T3 (da) Bakteriofaglysin
DE60328708D1 (de) Sol-gel-biosensoren
AR035881A1 (es) Un metodo para determinar la predisposicion de un individuo a una condicion de piel, un sistema para determinar dicha predisposicion, uso de un polipeptido que comprende la secuencia de un alelo de profilagrina, o una de sus variantes o fragmentos o un polinucleotido que codifica cualquiera de estos
Takashima et al. Analysis of sialyltransferase-like proteins from Oryza sativa
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
KR830003576A (ko) 인간의 프로인슐린선구물질과 프로인슐린 유전자를 분리, 정제하고 미생물에게 전달해서 복제하는 방법
Fernández et al. Molecular determinants of negative regulation of the Bradyrhizobium diazoefficiens transcription factor FixK 2
DK595187D0 (da) Minactivin og fremgangsmaade til fremstilling deraf
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
ATE474051T1 (de) Bakterien mit erhöhter proteinsekretion, nukleotidsequenzen codierend fur ein seca protein mit erhöhter proteinsekretion sowie verfahren zur produktion von proteinen